Grifols sees revenues rise after diagnostics boost
This article was originally published in Clinica
Executive Summary
Spain’s largest healthcare company Grifols saw sales increase by around 15% during the first nine months of 2009 after it was boosted by increased revenue from its diagnostics division. The firm recorded a 20% increase in diagnostics sales to €76.2m ($114.1m) during the nine-month period. Sales of Grifols’ reagents were the main drivers behind this increase. The group, which also develops pharma products, recorded overall revenue for the nine months of €689.6m, up from €600.2m during the same period the previous year. Overall net profit for the period was €117.1m, an improvement on €92.9m recorded in the first nine months of 2008.